About the Company
We do not have any company description for Estrella Immunopharma, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Estrella Immunopharma, Inc.
ESLA Estrella Immunopharma, Inc. - Seeking Alpha
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate ...
Estrella Immunopharma, Inc. (ESLA) Latest Stock News & Headlines ...
EMERYVILLE, Calif., June 05, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a ...
About Estrella Immunopharma, Inc. Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancers and autoimmune diseases.
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose ...
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW ... - Morningstar
About Estrella Immunopharma, Inc. Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancers and autoimmune diseases.
ESLA - Estrella Immunopharma Inc News | Morningstar
News Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Business Wire Jun 5, 2025, 12:00:00 PM ...
Estrella Immunopharma Announces Approximately $3.35 Million ... - Nasdaq
Estrella Immunopharma, Inc., a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, today announced that ...
Estrella Immunopharma Announces Appointment of Hong Zhang as ...
EMERYVILLE, Calif.-- ()--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T ...
Estrella Immunopharma Inc. Wt (ESLAW) Stock Price Today - WSJ
View the latest Estrella Immunopharma Inc. Wt (ESLAW) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Estrella Immunopharma Announces Appointment of Hong Zhang as ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", “Estrella Immunopharma”, or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22 ...
Similar Companies
Loading the latest forecasts...